• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacologic

Emily

Editor, Senior Moderator
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118492/
Tang B, Lo HH, Lei C, et al. Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease [published online ahead of print, 2020 Mar 18]. Phytomedicine. 2020;70:153208. doi:10.1016/j.phymed.2020.153208
Abstract


Background

Kawasaki disease (KD) is a self-limiting acute systemic vasculitis occur mainly in infants and young children under 5 years old. Although the use of acetylsalicylic acid (AAS) in combination with intravenous immunoglobulin (IVIG) remains the standard therapy to KD, the etiology, genetic susceptibility genes and pathogenic factors of KD are still un-elucidated.

Purpose

Current obstacles in the treatment of KD include the lack of standard clinical and genetic markers for early diagnosis, possible severe side effect of AAS (Reye's syndrome), and the refractory KD cases with resistance to IVIG therapy, therefore, this review has focused on introducing the current advances in the identification of genetic susceptibility genes, environmental factors, diagnostic markers and adjuvant pharmacological intervention for KD.

Results

With an overall update in the development of KD from different aspects, our current bioinformatics data has suggested CASP3, CD40 and TLR4 as the possible pathogenic factors or diagnostic markers of KD. Besides, a list of herbal medicines which may work as the adjunct therapy for KD via targeting different proposed molecular targets of KD have also been summarized.

Conclusion

With the aid of modern pharmacological research and technology, it is anticipated that novel therapeutic remedies, especially active herbal chemicals targeting precise clinical markers of KD could be developed for accurate diagnosis and treatment of the disease.

Keywords: Kawasaki disease, Epidemiology, Diagnostic marker, Susceptibility genes, Adjuvant therapy, Herbal chemicals

Abbreviations: AAS, acetylsalicylic acid; AHA, the American Heart Association; CALs, coronary artery lesions; CASP, caspase; CD, cluster of differentiation; CRP, C-reactive protein; DAVID, Database for Annotation, Visualization and Integrated Discovery; FCGR2A, Fc fragment of immunoglobulin G, low-affinity IIa; GWAS, genome-wide association method; HAdV, the human adenovirus; IL, Interleukin; ITPKC, inositol 1,4,5-triphosphate 3-kinase; C IVIG, intravenous immunoglobulin; KD, Kawasaki disease; MyD88, myeloid differentiation factor 88; NF-κB, nuclear factor κB; RS, Reye's syndrome; SNPs, single nucleotide polymorphisms; TCMs, traditional Chinese medicines; Th, T helper; TLR4, toll-like receptor 4; TNF, tumor necrosis factor
 
Back
Top